Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Price:
5.74
CNY
0.35%
Market Cap:
¥38.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
CN |
|
Rarex Ltd
ASX:REE
|
AU |
|
CVB Financial Corp
NASDAQ:CVBF
|
US |
|
Ichia Technologies Inc
TWSE:2402
|
TW |
|
C
|
CGN New Energy Holdings Co Ltd
HKEX:1811
|
HK |
|
Medicenna Therapeutics Corp
TSX:MDNA
|
CA |
|
Agronomics Ltd
LSE:ANIC
|
IM |
|
Blackbaud Inc
NASDAQ:BLKB
|
US |
|
National Health Investors Inc
NYSE:NHI
|
US |
|
Sayona Mining Ltd
ASX:SYA
|
AU |
|
Promotora Ambiental SAB de CV
BMV:PASAB
|
MX |
|
Y
|
Yeti Holdings Inc
SWB:1YN
|
US |
|
M
|
MFE-MEDIAFOREUROPE NV
MIL:MFEB
|
IT |
|
E
|
Evolution AB (publ)
F:E3G1
|
SE |
|
N
|
NEXR Technologies SE
XETRA:NXR
|
DE |
|
VRX Silica Ltd
ASX:VRX
|
AU |
|
Deceuninck NV
XBRU:DECB
|
BE |
Multiples-Based Value
The Multiples-Based Value of one
Shanghai RAAS Blood Products Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 5.74 CNY,
Shanghai RAAS Blood Products Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Shanghai RAAS Blood Products Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Shanghai RAAS Blood Products Co Ltd Competitors
Shanghai RAAS Blood Products Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
38.1B CNY | 5.2 | 24.2 | 25.4 | 25.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
367.6B USD | 6 | 87.8 | 14.6 | 20.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.2B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD | 5.9 | 20.3 | 12.7 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 9.2 | 28 | 21 | 22 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.2B EUR | 11.9 | 38.2 | 41.3 | 42.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 2.9 | 32.3 | 10.9 | 13.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
